Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL in Femoral Nerve Block f

Pacira Pharmaceuticals, Inc. Announces Positive Interim Analysis of EXPAREL ...DailyFinanceWe look forward to initiating the Phase 3 portion of this trial and ultimately to providing orthopedic patients with a new option that could significantly contribute to the management of their postsurgical pain by replacing a perineural catheter, drug ...http://www.dailyfinance.com/2013/05/29/pacira-pharmaceuticals-inc-announces-positive-inte/

Is This the Beginning of the End for Alzheimer's?

Is This the Beginning of the End for Alzheimer's?Motley FoolUnfortunately, no matter how promising drugs appear in phase 2 results, they fail in phase 3 trials without slowing the progression of this debilitating neurological disease. Now, researchers at the University of Cambridge have discovered the mechanism ...
http://www.fool.com/investing/general/2013/05/29/is-this-the-beginning-of-the-end-for-alzheimers.aspx

Sonepcizumab/LT1009-US-based Lpath has begun patient dosing in Phase 2a single-arm trial of anti-cancer drug, Asonep.

http://www.allfordrugs.com/2013/05/28/sonepcizumablt1009-us-based-lpath-has-begun-patient-dosing-in-phase-2a-single-arm-trial-of-anti-cancer-drug-asonep/

Gilead Sciences reported that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission.

http://www.allfordrugs.com/2013/05/29/gilead-sciences-reported-that-in-a-recent-phase-2-study-its-oral-drug-idelalisib-successfully-drove-the-life-threatening-chronic-lymphocytic-leukemia-cll-into-remission/
Gilead Sciences reported that in a recent Phase 2 study, its oral drug idelalisib successfully drove the life-threatening chronic lymphocytic leukemia (CLL) into remission.

Mitsubishi Tanabe seeks manufacturing, marketing approval for TA-7284, Canagliflozin in Japan

http://newdrugapprovals.wordpress.com/2013/05/28/mitsubishi-tanabe-seeks-manufacturing-marketing-approval-for-ta-7284-canagliflozin-in-japan/

Astellas Pharma and Medivation have announced the submission of application for marketing approval of enzalutamide in Japan for the treatment of prostate cancer

http://newdrugapprovals.wordpress.com/2013/05/28/astellas-pharma-and-medivation-have-announced-the-submission-of-application-for-marketing-approval-of-enzalutamide-in-japan-for-the-treatment-of-prostate-cancer/

TSRI develops new technique for finding therapeutic antibodies

http://newdrugapprovals.wordpress.com/2013/05/29/tsri-develops-new-technique-for-finding-therapeutic-antibodies/